🍪 CompoundTalk uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsSide Effects & ManagementPancreatitis risk assessment — pooled safety analysis

Pancreatitis risk assessment — pooled safety analysis

Dr.MetabolicMD Sun, Jun 7, 2026 at 2:11 AM 15 replies 291 viewsPage 1 of 3
Dr.MetabolicMD
VIP Member
2,345
16,789
Jan 2024
Rochester, MN
Jun 7, 2026 at 2:11 AM#1

Read the primary source rather than the write-up and the two do not agree, so here is what is actually in it.

Pooled safety analyses have not shown a clear excess of pancreatitis for this class, and the background rate in the population being treated is already elevated by obesity, gallstones and alcohol. That said, the labels carry the warning, and the presentation is distinctive enough to act on: severe persistent upper-abdominal pain radiating to the back, usually with vomiting, not relieved by anything.

Where I think it is weakest: the completion rate deserves as much attention as the headline, because a large effect among those who finished is a different claim from a large effect among those enrolled.

The question I want answered is what the pooled safety data actually shows for this class, as opposed to what the label warning implies. Not looking for reassurance. Looking for the part I have got wrong.

Note on sourcing:
Figures above are from the primary publication rather than the press summary. If a number here disagrees with one you have, post yours and we will work out which of us is reading a secondary source.
16 11SleepDoc_PDX, RegAffairsDC, BiostatsBrad and 13 others
Reply Quote Save Share Report
JessicaH_TX
Senior Member
4,123
13,456
Dec 2023
Houston, TX
Jun 7, 2026 at 2:13 AM#2
Dr.MetabolicMD said:
Pooled safety analyses have not shown a clear excess of pancreatitis for this class, and the background rate in the population being treated is…

Lipase monitoring while on pancreatitis risk: my doctor checks lipase every 3 months given the theoretical pancreatitis risk. All readings have been normal:

  • Baseline: 44 U/L
  • Month 3: 33 U/L
  • Month 6: 37 U/L
  • Month 9: 35 U/L

Normal range is 0-160 U/L. While clinical pancreatitis is rare (<0.5%), I find peace of mind in regular monitoring. Worth asking your doctor about if you're on a GLP-1 long-term.

15 10sarah_TO, wendy_avl, jason_paloalto and 12 others
Reply Quote Save Share Report
DataDave
Senior Member
1,678
8,901
Apr 2024
Washington
Online
Jun 7, 2026 at 2:14 AM#3
Dr.MetabolicMD said:
Pooled safety analyses have not shown a clear excess of pancreatitis for this class, and the background rate in the population being treated is…

Pancreatitis scare with pancreatitis risk: had severe upper abdominal pain radiating to my back at week 6. Went to the ER — they checked lipase and amylase, both normal. Turned out to be severe constipation.

But I'm glad I went. The risk of pancreatitis, while small (<0.5%), is real. Don't try to tough out severe abdominal pain on a GLP-1 agonist. Get checked.

Last edited: Jun 7, 2026 at 3:14 AM
14 9LondonLisa, mike_nyc, VendorMark and 11 others
Reply Quote Save Share Report

PeptideMeter — Independent Peptide Analytics

Community-driven peptide testing and vendor rating platform. Transparent results. Unbiased analysis. Trusted by thousands.

View Results
rachel_ABQ
Member
178
890
Dec 2024
Albuquerque, NM
Jun 7, 2026 at 2:16 AM#4

Short answer first, then the reasoning. It helps to ask what evidence would change your mind before you look at any. If nothing would, the discussion is not about evidence, and it is better to say so early than to spend nine posts discovering it.

13 8SkepticalSean, Dr.CardioMD, EndoResFellow and 10 others
Reply Quote Save Share Report
oliver_london
Member
312
1,345
Aug 2024
London, UK
Jun 7, 2026 at 2:25 AM#5
JessicaH_TX said:
Lipase monitoring while on pancreatitis risk: my doctor checks lipase every 3 months given the theoretical pancreatitis risk.

This matches mine closely enough to be worth saying so out loud.

Last edited: Jun 7, 2026 at 3:25 AM
12 7wendy_avl, jason_paloalto, Dr.LeslieOBGYN and 9 others
Reply Quote Save Share Report

Similar Threads

Nausea incidence by dose tier — STEP and SURMOUNT meta-analysis16 replies
Constipation on GLP-1: pathophysiology and fiber protocol5 replies
Alopecia on GLP-1 — telogen effluvium differential diagnosis3 replies
Gallbladder disease risk — cholelithiasis data from clinical trials12 replies
Fatigue on semaglutide — caloric deficit vs direct drug effect25 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register